{"id":37186,"date":"2025-07-11T15:10:29","date_gmt":"2025-07-11T07:10:29","guid":{"rendered":"https:\/\/flcube.com\/?p=37186"},"modified":"2025-07-11T15:10:30","modified_gmt":"2025-07-11T07:10:30","slug":"jcr-pharmaceuticals-signs-licensing-agreement-with-astrazenecas-alexion-for-just-aav-gene-therapy-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37186","title":{"rendered":"JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca&#8217;s Alexion for JUST-AAV Gene Therapy Platform"},"content":{"rendered":"\n<p>Japan-based JCR Pharmaceuticals Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/4552:TYO\">TYO: 4552<\/a>) announced a licensing agreement with UK-based AstraZeneca&#8217;s (<a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NASDAQ\">NASDAQ: AZN<\/a>) rare disease subsidiary Alexion for its proprietary JUST-AAV capsid platform. The platform will be used in up to five gene therapy development programs, marking a significant step forward in the field of gene therapy.<\/p>\n\n\n\n<p><strong>Innovative JUST-AAV Technology<\/strong><br>The JUST-AAV platform is an innovative technology that utilizes engineered adeno-associated virus (AAV) vectors. By incorporating mini-antibodies into the capsid surface to target specific receptors in tissues, organs, or the blood-brain barrier, the platform enhances targeted delivery, potentially improving the precision and safety of gene therapies.<\/p>\n\n\n\n<p><strong>Financial Terms of the Agreement<\/strong><br>Under the agreement, JCR will receive an upfront payment and is eligible for milestone payments totaling up to USD 825 million. This includes up to USD 225 million for development milestones and up to USD 600 million for sales-based milestones. Additionally, JCR will receive tiered royalties based on the net sales of any resulting products.<\/p>\n\n\n\n<p><strong>History of Collaboration<\/strong><br>This transaction marks the third collaboration between JCR and Alexion. Previous partnerships involved J-Brain Cargo technology for the development of neurodegenerative disease therapies and oligonucleotide therapeutics respectively.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/JCR-pharmaceuticals-enters-license-agreement-with-Alexion-for-proprietary-JUST-AAV-capsids-to-be-used-in-the-development-of-genomic-medicines.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of JCR-pharmaceuticals-enters-license-agreement-with-Alexion-for-proprietary-JUST-AAV-capsids-to-be-used-in-the-development-of-genomic-medicines.\"><\/object><a id=\"wp-block-file--media-a98788d8-765d-44b1-86eb-0e72b35ba6d5\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/JCR-pharmaceuticals-enters-license-agreement-with-Alexion-for-proprietary-JUST-AAV-capsids-to-be-used-in-the-development-of-genomic-medicines.pdf\">JCR-pharmaceuticals-enters-license-agreement-with-Alexion-for-proprietary-JUST-AAV-capsids-to-be-used-in-the-development-of-genomic-medicines<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/JCR-pharmaceuticals-enters-license-agreement-with-Alexion-for-proprietary-JUST-AAV-capsids-to-be-used-in-the-development-of-genomic-medicines.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a98788d8-765d-44b1-86eb-0e72b35ba6d5\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Japan-based JCR Pharmaceuticals Co., Ltd. (TYO: 4552) announced a licensing agreement with UK-based AstraZeneca&#8217;s (NASDAQ:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37190,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[130,1778,871,1779],"class_list":["post-37186","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-astrazeneca","tag-jcr-pharmaceuticals","tag-nasdaq-azn","tag-tyo-4552"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca&#039;s Alexion for JUST-AAV Gene Therapy Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japan-based JCR Pharmaceuticals Co., Ltd. (TYO: 4552) announced a licensing agreement with UK-based AstraZeneca&#039;s (NASDAQ: AZN) rare disease subsidiary Alexion for its proprietary JUST-AAV capsid platform. The platform will be used in up to five gene therapy development programs, marking a significant step forward in the field of gene therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37186\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca&#039;s Alexion for JUST-AAV Gene Therapy Platform\" \/>\n<meta property=\"og:description\" content=\"Japan-based JCR Pharmaceuticals Co., Ltd. (TYO: 4552) announced a licensing agreement with UK-based AstraZeneca&#039;s (NASDAQ: AZN) rare disease subsidiary Alexion for its proprietary JUST-AAV capsid platform. The platform will be used in up to five gene therapy development programs, marking a significant step forward in the field of gene therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37186\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-11T07:10:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-11T07:10:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1110.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37186#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37186\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca&#8217;s Alexion for JUST-AAV Gene Therapy Platform\",\"datePublished\":\"2025-07-11T07:10:29+00:00\",\"dateModified\":\"2025-07-11T07:10:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37186\"},\"wordCount\":206,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37186#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1110.webp\",\"keywords\":[\"AstraZeneca\",\"JCR Pharmaceuticals\",\"NASDAQ: AZN\",\"TYO: 4552\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37186#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37186\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37186\",\"name\":\"JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca's Alexion for JUST-AAV Gene Therapy Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37186#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37186#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1110.webp\",\"datePublished\":\"2025-07-11T07:10:29+00:00\",\"dateModified\":\"2025-07-11T07:10:30+00:00\",\"description\":\"Japan-based JCR Pharmaceuticals Co., Ltd. (TYO: 4552) announced a licensing agreement with UK-based AstraZeneca's (NASDAQ: AZN) rare disease subsidiary Alexion for its proprietary JUST-AAV capsid platform. The platform will be used in up to five gene therapy development programs, marking a significant step forward in the field of gene therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37186#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37186\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37186#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1110.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1110.webp\",\"width\":1080,\"height\":608,\"caption\":\"JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca's Alexion for JUST-AAV Gene Therapy Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37186#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca&#8217;s Alexion for JUST-AAV Gene Therapy Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca's Alexion for JUST-AAV Gene Therapy Platform - Insight, China&#039;s Pharmaceutical Industry","description":"Japan-based JCR Pharmaceuticals Co., Ltd. (TYO: 4552) announced a licensing agreement with UK-based AstraZeneca's (NASDAQ: AZN) rare disease subsidiary Alexion for its proprietary JUST-AAV capsid platform. The platform will be used in up to five gene therapy development programs, marking a significant step forward in the field of gene therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37186","og_locale":"en_US","og_type":"article","og_title":"JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca's Alexion for JUST-AAV Gene Therapy Platform","og_description":"Japan-based JCR Pharmaceuticals Co., Ltd. (TYO: 4552) announced a licensing agreement with UK-based AstraZeneca's (NASDAQ: AZN) rare disease subsidiary Alexion for its proprietary JUST-AAV capsid platform. The platform will be used in up to five gene therapy development programs, marking a significant step forward in the field of gene therapy.","og_url":"https:\/\/flcube.com\/?p=37186","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-11T07:10:29+00:00","article_modified_time":"2025-07-11T07:10:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1110.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37186#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37186"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca&#8217;s Alexion for JUST-AAV Gene Therapy Platform","datePublished":"2025-07-11T07:10:29+00:00","dateModified":"2025-07-11T07:10:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37186"},"wordCount":206,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37186#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1110.webp","keywords":["AstraZeneca","JCR Pharmaceuticals","NASDAQ: AZN","TYO: 4552"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37186#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37186","url":"https:\/\/flcube.com\/?p=37186","name":"JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca's Alexion for JUST-AAV Gene Therapy Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37186#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37186#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1110.webp","datePublished":"2025-07-11T07:10:29+00:00","dateModified":"2025-07-11T07:10:30+00:00","description":"Japan-based JCR Pharmaceuticals Co., Ltd. (TYO: 4552) announced a licensing agreement with UK-based AstraZeneca's (NASDAQ: AZN) rare disease subsidiary Alexion for its proprietary JUST-AAV capsid platform. The platform will be used in up to five gene therapy development programs, marking a significant step forward in the field of gene therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37186#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37186"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37186#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1110.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1110.webp","width":1080,"height":608,"caption":"JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca's Alexion for JUST-AAV Gene Therapy Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37186#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"JCR Pharmaceuticals Signs Licensing Agreement with AstraZeneca&#8217;s Alexion for JUST-AAV Gene Therapy Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1110.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37186"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37186\/revisions"}],"predecessor-version":[{"id":37191,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37186\/revisions\/37191"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37190"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}